Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males

Ubrogepant is a novel, oral calcitonin gene‐related peptide (CGRP) receptor antagonist intended for the acute treatment of migraine attacks. Ubrogepant has a chemical structure distinct from previous small‐molecule CGRP receptor antagonists that were associated with elevated serum alanine aminotrans...

Descripción completa

Detalles Bibliográficos
Autores principales: Ankrom, Wendy, Bondiskey, Phung, Li, Chi‐Chung, Palcza, John, Liu, Wen, Dockendorf, Marissa F., Matthews, Catherine, Panebianco, Deborah, Reynders, Tom, Wagner, John A., Jakate, Abhijeet, Mesens, Sofie, Kraft, Walter K., Marcantonio, Eugene E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214647/
https://www.ncbi.nlm.nih.gov/pubmed/31899602
http://dx.doi.org/10.1111/cts.12728

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214647/
https://www.ncbi.nlm.nih.gov/pubmed/31899602
http://dx.doi.org/10.1111/cts.12728

Ejemplares similares